Browse > Article

An Analysis of Medical Costs of Diabetic Patients in a University Hospital (1996-2005)  

Chun, Ki-Hong (Department of Preventive Medicine and Public Health, Ajou University School of Medicine)
Lee, Kwan-Woo (Department of Endocrinology and Metabolism, Ajou University School of Medicine)
Kim, Dae-Jung (Department of Endocrinology and Metabolism, Ajou University School of Medicine)
Kim, Hae-Jin (Department of Endocrinology and Metabolism, Ajou University School of Medicine)
Paek, Kyung-Won (Division of Social Welfare, Baekseok University)
Lee, Soo-Jin (Department of Preventive Medicine and Public Health, Ajou University School of Medicine)
Abstract
Background: The aim of this research was to find out the costs of diabetes, as research in a prospective cohort study looking into the development of diabetic complications followed by treatment intervention by a medical institution. The research compared the changes in medical costs by following-up on the treatment details of diagnosed diabetes for the last 10 years in a university hospital. Methods: The research used data of outpatient, inpatient, pharmaceutical and total medical costs, from 1996 to 2005, of individual patients who were diagnosed with diabetic patients, to analyze the outpatient and inpatient total medical cost changes over the years. Results: After antidiabetic drug, in the case of outpatient treatment, pharmaceutical costs increased on average by about 25,000 won a month for diabetic patients without complications and by 35,000 won for diabetic patients with microvascular complications. Outpatient medical costs were affected after drug treatment by as much of an increase as created by the pharmaceutical costs. The total medical costs, that is the sum of inpatient and outpatient costs, decreased by 30~40% compared to that before drug treatment. In the case of total medical cost, MI or ESRD cost 2~3 times more in pharmaceutical costs than before the development of complications. The total medical costs of diabetic patients with CVA, MI and ESRD complications increased in the first year after development of the complication, and this was followed by a decrease in the next year, showing a tendency to remain constant with no increase or decrease over subsequent years. This means that the total medical costs of patients with complications remain continuously large throughout the life of the diagnosed patient. Conclusion: For diabetic patients, pharmaceutical costs are the most important factor in determining outpatient medical costs. (KOREAN DIABETES J 32:366-376, 2008)
Keywords
Diabetes; Medical costs; Pharmaceutical costs
Citations & Related Records
연도 인용수 순위
  • Reference
1 International Diabetes Federation: Diabetes Atlas. 2nd ed. 2003
2 U.K. Prospective Diabetes Study Group: U .K. Prospective Diabetes Study 16: Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 44:1249-58, 1995   DOI   ScienceOn
3 David CK, Daniel MS: An Economic Analysis of Interventions for Diabetes. Diabetes Care 23:390-404, 2000   DOI   ScienceOn
4 Marcia AT, Donald CS: Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients with Type 2 Diabetes Mellitus. JAMA 280:1490-6, 1998   DOI   ScienceOn
5 U.K. Prospective Diabetes Study Group: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41). BMJ 320:1373-8. 2000   DOI   ScienceOn
6 연세대학교 보건정책 및 관리연구소: 우리나라 당뇨병 환자의 기초 역학 자료 및 합병증 진료비조사. 2004
7 Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-12, 2000   DOI   ScienceOn
8 The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin -dependent diabetes mellitus. N Engl J Med 329:977-86, 1993   DOI   ScienceOn
9 윤건호: 제2형 당뇨병을 동반한 고혈압 환자의 치료 가이드라인. Diabetes Research Digest 1:23-30, 2004   DOI   ScienceOn
10 American diabetes association: Economic costs of diabetes in the U.S. in 2002. Diabetes care 26:917-32, 2003   DOI   ScienceOn
11 Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KD: The Economic Cost of Diabetes in Canada, 1998. Diabetes Care 25:1303-7, 2002   DOI   ScienceOn
12 O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ: Direct Medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 21:1122-8, 1998   DOI   ScienceOn
13 당뇨병 기초통계연구 Task Force Team: Diabetes in Korea 2007: 당뇨병 기초통계연구 Task Force Team 보고서 1st ed. p.64, 서울, 황금어장, 2007
14 Zhang P, Engelgau MM, Noris SL, Gregg EW, Venkat Narayan KM: Application of Economic Analysis to Diabetes and Diabetes Care. Ann Intern Med 140:972-7, 2004   DOI   ScienceOn
15 대한당뇨병학회: 당뇨병학. p. 415, 고려의학, 2005
16 정영호, 고숙자: 5대 사망원인 질병의 사회.경제적 비용추계. 재정논집 18:77-104, 2003
17 Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, Solberg LI: Predictors of health care costs in adults with diabetes. Diabetes Care 28:59-64, 2005   DOI   ScienceOn